{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:46:39Z","timestamp":1785818799715,"version":"3.56.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i), as key therapeutic agents for type 2 diabetes, have in recent years been recognized as potentially exerting neuroprotective effects on the central nervous system. However, systematic comparative evidence remains lacking regarding whether different SGLT2i exhibit differential effects on dementia risk. By conducting a network meta-analysis to compare the association between different SGLT2i and the risk of dementia onset, the relative efficacy of each drug in reducing dementia risk is determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted across databases including PubMed, Embase, Web of Science, and the Cochrane Library, from their inception to the search cutoff date of 1 December 2025. Randomized controlled trials and observational studies comparing SGLT2i with other antidiabetic medications or placebo, and reporting dementia outcomes, were included. A network meta-analysis employing a random-effects model was conducted. Pooled effect sizes were expressed as hazard ratios with 95% confidence intervals. Relative efficacy among different drugs was ranked using the probability of ranking, whilst heterogeneity and consistency were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six cohort studies involving 845,433 patients were included in this analysis. The results of the network meta-analysis indicated that canagliflozin (HR\u00a0=\u00a00.75, 95% CrI: 0.59, 0.98), Dapagliflozin (HR\u00a0=\u00a00.75, 95% CrI: 0.59, 0.98), and Empagliflozin (HR\u00a0=\u00a00.69, 95% CrI: 0.55, 0.85) significantly reduced the risk of dementia onset. Empagliflozin had the highest probability of being ranked as the most effective treatment (81.2%). However, no statistically significant differences were observed between empagliflozin and dapagliflozin or canagliflozin in the network comparisons. For Alzheimer\u2019s disease, Dapagliflozin (HR\u00a0=\u00a00.68, 95% CrI: 0.48, 0.96) and Empagliflozin (HR\u00a0=\u00a00.62, 95% CrI: 0.45, 0.87) also demonstrated significant risk reduction, whilst direct comparisons between Empagliflozin and other agents showed no significant differences. For vascular dementia, Empagliflozin (HR\u00a0=\u00a00.63, 95% CrI: 0.46, 0.87) and Canagliflozin (HR\u00a0=\u00a00.71, 95% CrI: 0.48, 0.98) also demonstrated favorable outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings of this study indicate that dapagliflozin, empagliflozin, and canagliflozin, particularly empagliflozin, demonstrate significant potential in reducing the incidence of dementia and related cognitive impairments. Compared with DPP-4 inhibitors, these agents effectively lower the risk of dementia, Alzheimer\u2019s disease, and vascular dementia, offering an effective therapeutic option for diabetic patients, particularly the elderly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1777151","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:27:21Z","timestamp":1785817641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between different sodium\u2013glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhongru","family":"Meng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Yancheng First Hospital Affiliated to Nanjing University Medical School - Yancheng First People\u2019s Hospital","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yancheng First Hospital Affiliated to Nanjing University Medical School - Yancheng First People\u2019s Hospital","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yancheng First Hospital Affiliated to Nanjing University Medical School - Yancheng First People\u2019s Hospital","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yancheng First Hospital Affiliated to Nanjing University Medical School - Yancheng First People\u2019s Hospital","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yancheng First Hospital Affiliated to Nanjing University Medical School - Yancheng First People\u2019s Hospital","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.1016\/j.cell.2024.08.019","article-title":"Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics","volume":"187","author":"Rexach","year":"2024","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-025-00837-w","article-title":"Research models to study lewy body dementia","volume":"20","author":"Boschen","year":"2025","journal-title":"Mol Neurodegener"},{"key":"B3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41582-025-01090-x","article-title":"Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important","volume":"21","author":"Fu","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2024.10.013","article-title":"Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer's and related dementias","volume":"112","author":"Oh","year":"2024","journal-title":"Neuron"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102380","article-title":"A review of the literature on wellbeing and modifiable dementia risk factors","volume":"99","author":"Willroth","year":"2024","journal-title":"Ageing Res Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/14791641221098168","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study","volume":"19","author":"Siao","year":"2022","journal-title":"Diabetes Vasc Dis Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2024.101131","article-title":"Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"73","author":"Youn","year":"2024","journal-title":"Front Neuroendocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083039","article-title":"Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis","volume":"390","author":"Nong","year":"2025","journal-title":"Bmj"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199568741.003.0163","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"Herrington","year":"2025","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1652","article-title":"Disparities in sodium-glucose cotransporter 2 (SGLT2) inhibitor prescription and dispensing in the Israeli population-A retrospective cohort study","volume":"47","author":"Weissman","year":"2024","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: A population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14048","article-title":"Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population-based cohort study","volume":"20","author":"Tang","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14353","article-title":"Sodium-glucose cotransporter-2 inhibitors use and risk of dementia in different ethnoracial groups with type 2 diabetes","volume":"21","author":"Yang","year":"2025","journal-title":"Alzheimers Dement"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70182","article-title":"Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta-analysis","volume":"28","author":"Kato","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1695075","article-title":"Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Song","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of\u00a0the\u00a0quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.25431","article-title":"Markov chain Monte Carlo methods for hierarchical clustering of dynamic causal models","volume":"42","author":"Yao","year":"2021","journal-title":"Hum Brain Mapp"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004541","article-title":"Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study","volume":"13","author":"Abdullah","year":"2025","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108276","article-title":"Comparative risk of dementia in diabetic stroke patients prescribed SGLT2 vs. DPP-4 inhibitors: A propensity-matched retrospective cohort study","volume":"34","author":"Chiang","year":"2025","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101581","article-title":"Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study","volume":"50","author":"Hong","year":"2024","journal-title":"Diabetes Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112197","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A five-year retrospective cohort analysis of 160,752 patients","volume":"224","author":"Liu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0353","article-title":"GLP-1RA and SGLT2i medications for type 2 diabetes and alzheimer disease and related dementias","volume":"82","author":"Tang","year":"2025","journal-title":"JAMA Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06595-0","article-title":"Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes","volume":"2","author":"Wu","year":"2025","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2064","article-title":"Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: A 16-week randomized parallel comparative study","volume":"45","author":"Cheng","year":"2022","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100199","article-title":"New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study","volume":"12","author":"Cohen","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. Dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: A propensity score-matched population-based study with competing risk analysis","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70621","article-title":"GLP-1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi-site cohort of patients with type 2 diabetes","volume":"21","author":"Nance","year":"2025","journal-title":"Alzheimers Dement"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3233\/jad-200618","article-title":"Dementia diagnosis is associated with changes in antidiabetic drug prescription: an open-cohort study of \u223c130,000 swedish subjects over 14 years","volume":"76","author":"Secnik","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101655","article-title":"Comparative study of SGLT2 inhibitors and metformin: Evaluating first-line therapies for dementia prevention in type 2 diabetes","volume":"51","author":"Sun","year":"2025","journal-title":"Diabetes Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/eje-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16239","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and risk of dementia: A population-based cohort study","volume":"27","author":"Zhuo","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.7326\/M23-3220","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia A population-based cohort study","volume":"177","author":"Hong","year":"2024","journal-title":"Ann Internal Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1777151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:27:22Z","timestamp":1785817642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1777151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":35,"alternative-id":["10.3389\/fendo.2026.1777151"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1777151","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1777151"}}